NCT02019784View on ClinicalTrials.gov

Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions
Liver CirrhosisHepatoencephalopathy, Early Fatal Progressive
Interventions
DRUG

Rifaximin-α

Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.

DRUG

Placebo Oral Tablet

Placebo Oral Tablet

Trial Locations (1)

SE5 9RS

King's College Hospital NHS Foundation Trust, London

All Listed Sponsors
collaborator

King's College London

OTHER

lead

King's College Hospital NHS Trust

OTHER

NCT02019784 - Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter